Skip to main content
Top
Published in: Current HIV/AIDS Reports 2/2015

01-06-2015 | The Global Epidemic (SH Vermund, Section Editor)

A Political and Social History of HIV in South Africa

Authors: Nono Simelela, W. D. Francois Venter, Yogan Pillay, Peter Barron

Published in: Current HIV/AIDS Reports | Issue 2/2015

Login to get access

Abstract

For the past 25 years, South Africa has had to deal with the inexorable and monumental rise of HIV. From one or two isolated cases, in the late 1980s, South Africa now has an estimated 6.4 million people infected with HIV, with high rates of concomitant tuberculosis, which will profoundly affect the country for decades to come. For nearly 10 years, the South African government’s response to the HIV epidemic was described as denialist, which was estimated to have resulted in the deaths of 330,000 people because lifesaving antiretroviral therapy (ART) was not provided (Chigwedere et al. J Acquir Immune Defic Syndr. 49:410–15, 2008; Heywood 2004). However, the story of the HIV and AIDS response in South Africa over the past 5 years is one of great progress after almost a decade of complex and tragic denialism that united civil society in a way not seen since the opposition to apartheid. Today, South Africa can boast of close to 3 million people on ART, by far the largest number in the world. Prevention efforts appear to be yielding results but there continues to be large numbers of new infections, with a profound peak in incidence in young women aged 15 to 24 years. In addition, infections occur across the gender spectrum in older age groups. As a result of the massive increase in access to ART after 2004 and particularly after 2008 as political will towards the HIV ART programme improved, there has been a marked increase in life expectancy, from 56 to 61 years in the period 2009–2012 alone; the aggressive expansion of the prevention of mother to child transmission (PMTCT) to HIV-positive pregnant women has been accompanied by dramatic decrease in HIV transmission to infants; and a 25 % decrease in child and infant mortality rates in the period 2009–2012. This progress in access is significantly due to a civil society movement that was prepared to pose a rights-based challenge to a governing party in denial and to brave health officials, politicians and clinicians working in a hostile system to bring about change.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chigwedere P, Seage GR, Gruskin S, Lee T-H. Estimating the lost benefits of antiretroviral drug use in South Africa. Perspectives: Epidemiology and Social Science. J Acquir Immune Defic Syndr. 2008;49:410–5 (accessed 28 January 2015).CrossRefPubMed Chigwedere P, Seage GR, Gruskin S, Lee T-H. Estimating the lost benefits of antiretroviral drug use in South Africa. Perspectives: Epidemiology and Social Science. J Acquir Immune Defic Syndr. 2008;49:410–5 (accessed 28 January 2015).CrossRefPubMed
3.
go back to reference Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Labadarios D, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town: HSRC Press; 2014. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Labadarios D, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town: HSRC Press; 2014.
4.
go back to reference Department of Health. The 2012 National Antenatal Sentinel HIV and Herpes Simplex type-2 prevalence Survey. South African National Department of Health; 2013. Department of Health. The 2012 National Antenatal Sentinel HIV and Herpes Simplex type-2 prevalence Survey. South African National Department of Health; 2013.
6.
go back to reference Ras GJ, Simson W, Anderson R, Prozesky OW, Hammersma T. Acquired immunodeficiency syndrome: a report of 2 South African cases. S Afr Med J. 1983;64(4):140–4.PubMed Ras GJ, Simson W, Anderson R, Prozesky OW, Hammersma T. Acquired immunodeficiency syndrome: a report of 2 South African cases. S Afr Med J. 1983;64(4):140–4.PubMed
23.•
go back to reference Dorrington RE, Bradshaw D, Laubscher R. Rapid mortality surveillance report 2012. Cape Town: South African Medical Research Council; 2014. ISBN: 978-1-920618-19-3. This work shows how much progress has been made in South Africa with respect to HIV. It quantifies the improvement in public health indicators and the health systems’ response to HIV. Dorrington RE, Bradshaw D, Laubscher R. Rapid mortality surveillance report 2012. Cape Town: South African Medical Research Council; 2014. ISBN: 978-1-920618-19-3. This work shows how much progress has been made in South Africa with respect to HIV. It quantifies the improvement in public health indicators and the health systems’ response to HIV.
24.
go back to reference Goga AE, Dinh TH, Jackson DJ for the SAPMTCTE study group. Early (4–8 weeks post-delivery). Population-level Effectiveness of WHO PMTCT Option A, South Africa, 2011. South African Medical Research Council, National Department of Health of South Africa and PEPFAR/US Centers for Disease Control and Prevention; 2013. http://www.mrc.ac.za/healthsystems/SAPMTCTE2011.pdf. Accessed 21 Jan 2015. Goga AE, Dinh TH, Jackson DJ for the SAPMTCTE study group. Early (4–8 weeks post-delivery). Population-level Effectiveness of WHO PMTCT Option A, South Africa, 2011. South African Medical Research Council, National Department of Health of South Africa and PEPFAR/US Centers for Disease Control and Prevention; 2013. http://​www.​mrc.​ac.​za/​healthsystems/​SAPMTCTE2011.​pdf. Accessed 21 Jan 2015.
26.
go back to reference Meyer-Rath G, Over M. HIV treatment as prevention: Modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med. 2012;9(7):e1001247.CrossRefPubMedCentralPubMed Meyer-Rath G, Over M. HIV treatment as prevention: Modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med. 2012;9(7):e1001247.CrossRefPubMedCentralPubMed
28.•
go back to reference Mayosi BM, Lawn JE, van Niekerk A, Lancet South Africa team, et al. Health in South Africa: Changes and challenges since 2009. Lancet. 2012;380(9858):2029–43. This work shows how much progress has been made in South Africa with respect to HIV. It quantifies the improvement in public health indicators and the health systems’ response to HIV.CrossRefPubMed Mayosi BM, Lawn JE, van Niekerk A, Lancet South Africa team, et al. Health in South Africa: Changes and challenges since 2009. Lancet. 2012;380(9858):2029–43. This work shows how much progress has been made in South Africa with respect to HIV. It quantifies the improvement in public health indicators and the health systems’ response to HIV.CrossRefPubMed
29.
go back to reference Simelela NP, Venter WDF. A brief history of South Africa’s AIDS response. S Afr Med J. 2014;104(3 Suppl 1):249–51.CrossRefPubMed Simelela NP, Venter WDF. A brief history of South Africa’s AIDS response. S Afr Med J. 2014;104(3 Suppl 1):249–51.CrossRefPubMed
Metadata
Title
A Political and Social History of HIV in South Africa
Authors
Nono Simelela
W. D. Francois Venter
Yogan Pillay
Peter Barron
Publication date
01-06-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 2/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0259-7

Other articles of this Issue 2/2015

Current HIV/AIDS Reports 2/2015 Go to the issue

Central Nervous System and Cognition (SS Spudich, Section Editor)

The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication

The Global Epidemic (SH Vermund, Section Editor)

Inflammation and HIV Transmission in Sub-Saharan Africa

Central Nervous System and Cognition (SS Spudich, Section Editor)

Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine